Starling Oncology lifts FY 2026 revenue outlook to $650-$670 million - TOI News | RalliesStarling Oncology lifts FY 2026 revenue outlook to $650-$670 million
T
TOI• Raised 2026 guidance
- The Oncology Institute raised full-year 2026 revenue guidance to $650-$670 million from $630-$650 million.
- Gross profit forecast increased to $105-$110 million from $97-$107 million.
- Adjusted EBITDA outlook narrowed to $2-$7 million from $0-$9 million.
- Free cash flow guidance held at $5-$15 million.
Second-quarter results
- Update follows Q2 revenue of $161.3 million, gross profit of $27.2 million, net loss of $9.8 million, adjusted EBITDA of USD 0.23 million.
•
